LY011
Phase 1Biologic
LY011 is one of 84 biologic programs targeting Gastric Adenocarcinoma. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Gemzar
GGynecologic Oncology Group
Preclinical
MS Contin
Merck & Co.Preclinical
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
Chemotherapy Agents
TakedaPreclinical
LDE225
NovartisPreclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY011. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details